Kumar, Saumya https://orcid.org/0000-0001-9481-1944
Li, Chaofan https://orcid.org/0000-0002-5426-1498
Zhou, Liang
Zhan, Qiuyao
Alaswad, Ahmed
Volland, Sonja https://orcid.org/0009-0007-4324-2180
Costa, Bibiana https://orcid.org/0009-0002-6126-6075
Krooss, Simon Alexander
Klefenz, Isabel https://orcid.org/0009-0006-8223-2439
Schmaus, Hagen
Zeuzem, Antonia
von Witzendorff, Dorothee
Lickei, Helena
Pueschel, Lea https://orcid.org/0009-0000-6807-2615
Kraft, Anke R. M. https://orcid.org/0000-0002-9666-0753
Cornberg, Markus https://orcid.org/0000-0002-9141-8001
Koczulla, Andreas Rembert
Pink, Isabell
Hoeper, Marius M. https://orcid.org/0000-0001-9086-2293
Xu, Cheng-Jian
Häussler, Susanne
Wiestler, Miriam https://orcid.org/0000-0002-7644-1529
Netea, Mihai G. https://orcid.org/0000-0003-2421-6052
Illig, Thomas
Article History
Received: 17 March 2025
Accepted: 3 December 2025
First Online: 14 January 2026
Competing interests
: M.G.N. is the scientific founder of Biotrip, Salvina, TTxD and Lemba. MHH has received fees for consultations or lectures from 35Pharma, Acceleron, Actelion, Aerovate, AOP Health, Bayer, Ferrer, Gossamer, Inhibikase, Janssen, Keros, MSD and Novartis. The other authors declare no competing interests.